Stocks · News reference

Tiziana Life Sciences To Present Poster, Titled Phase 2a Trial Of Intranasal Foralumab – BANYAN, A Healey ALS MyMatch Trial, At ALS Nexus 2026

Aug 24, 2026, 11:04 AMBenzinga Newsdesk

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 24, 2026, 11:04 AM
Checked: Aug 24, 2026, 1:28 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 4, 2026, 11:10 AMBenzinga Newsdesk
Tiziana Life Sciences Announces CEO Ivor Elrifi Purchased 667,000 Common Shares At $1.00 Per Share, Raising Total Holding To 4,472,261 Shares
Read original at benzinga
TLSA
BenzingaJul 31, 2026, 5:32 PMVandana Singh
Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition
Tiziana Life Sciences reports reduced brain inflammation in its third Phase 2 trial patient treated with intranasal foralumab for MSA.
Read original at benzinga
TLSA
BenzingaJul 31, 2026, 1:55 PMBenzinga Newsdesk
Tiziana Life Sciences shares are trading higher after the company announced quantitative PET imaging results from the third patient with Multiple System Atrophy in the Phase 2 clinical trial treated with intranasal foralumab to complete dosing.
Read original at benzinga
TLSA